Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Eli Lilly and Company (NYSE:LLY – Get Free Report) had its target price lowered by equities researchers at Citigroup from ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $732 billion, has been ...

The company disclosed preliminary results in mid January, but it left out important metrics such as earnings per share for the fourth quarter.

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Jim Cramer, the host of Mad Money, discussed the upcoming market and corporate activity to look forward to this week, which ...

Analysts at Deutsche Bank upgraded the Eli Lilly (NYSE:LLY) stock from Hold to Buy on Monday and raised their price target from $725 to $1,025, implying an upside potential of 15% ...

On Friday, Guggenheim analysts revised their price target for Eli Lilly (NYSE:LLY) shares, reducing it to $973.00 from the previous $995.00, while reiterating a Buy rating on the ...

Eli Lilly has revised its revenue forecast for 2024 after seeing weaker ... slowdown to a lower-than-expected amount of the drugs in stock at the end of the year and changes to Medicare Part ...

Luckily, the hiring process proceeded smoothly and Charles van Zyl joined as chief executive from Belgian pharma company UCB ...

Erste Group upgraded Eli Lilly (LLY) to Buy from Hold. Eli Lilly has products that are in high demand as well as “an extensive pipeline of ...